Cargando…

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

OBJECTIVES: The efficacy and safety of certolizumab pegol (CZP), an Fc-free, PEGylated anti-TNF, in axial spondyloarthritis (axSpA) has been established in clinical trial settings. We report CZP effectiveness and safety in European clinical practice in patients with axSpA, including radiographic (r-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baraliakos, Xenofon, Witte, Torsten, De Clerck, Luc, Frediani, Bruno, Collantes-Estévez, Eduardo, Katsifis, Gkikas, VanLunen, Brenda, Kleine, Elisabeth, Hoepken, Bengt, Bauer, Lars, Goodson, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785316/ https://www.ncbi.nlm.nih.gov/pubmed/32584415 http://dx.doi.org/10.1093/rheumatology/keaa181

Ejemplares similares

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW
por: van der Horst-Bruinsma, Irene, et al.
Publicado: (2020)

Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study
por: Katsifis, Gkikas, et al.
Publicado: (2022)

Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study
por: Baraliakos, Xenofon, et al.
Publicado: (2021)

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
por: Landewé, Robert, et al.
Publicado: (2020)

Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol
por: Maksymowych, Walter P., et al.
Publicado: (2021)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Active axial spondyloarthritis: potential role of certolizumab pegol
por: Ranatunga, Sriya, et al.
Publicado: (2014)

Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative Review
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2022)

Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis
por: Braun, Jürgen, et al.
Publicado: (2017)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
por: Sieper, J., et al.
Publicado: (2015)

Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
por: Marin, Josefina, et al.
Publicado: (2018)

Correction: Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
Publicado: (2020)

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study
por: Robinson, Philip C., et al.
Publicado: (2022)

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2021)

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
por: Keystone, Edward, et al.
Publicado: (2014)

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
por: van der Heijde, D., et al.
Publicado: (2017)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
por: Landewé, R, et al.
Publicado: (2014)

The Role of Imaging in Diagnosing Axial Spondyloarthritis
por: Khmelinskii, Nikita, et al.
Publicado: (2018)

Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis
por: Tsiami, Styliani, et al.
Publicado: (2022)

Central nervous system vasculitis in a patient with axial spondyloarthritis treated with infliximab: A case report and literature review
por: Panagopoulos, Panagiotis, et al.
Publicado: (2022)

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
por: Carron, Philippe, et al.
Publicado: (2016)

5. Certolizumab Pegol for RA in pregnancy
por: Thorne, Iona, et al.
Publicado: (2017)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
por: Baysal, Mehmet, et al.
Publicado: (2018)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Anti-CD74 IgA autoantibodies in radiographic axial spondyloarthritis: a longitudinal Swedish study
por: Do, Lan, et al.
Publicado: (2020)

Added Value of Anti-CD74 Autoantibodies in Axial SpondyloArthritis in a Population With Low HLA-B27 Prevalence
por: Ziade, Nelly R., et al.
Publicado: (2019)

(99m)Tc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study
por: Lambert, Bieke, et al.
Publicado: (2016)

Editorial: Clinical manifestations and comorbidities in axial and peripheral spondyloarthritis
por: Schiotis, Ruxandra Elena, et al.
Publicado: (2022)

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
por: Curtis, Jeffrey R, et al.
Publicado: (2019)

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
por: Colombo, Elisabetta, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_6lrp1vjfudd9k42ln6ldooi441